拉替拉韦含药方案在接受利福平抗结核治疗的 4 周到 2 岁人类免疫缺陷病毒感染儿童中的药代动力学和安全性。
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
机构信息
Departments of Pediatrics and Molecular and Medical Pharmacology, David Geffen School of Medicine at Los Angeles, Los Angeles, California, USA.
Statistical and Data Management Center, Frontier Science Foundation/Harvard T.H. Chan School of Public Health Boston, Massachusetts, USA.
出版信息
J Pediatric Infect Dis Soc. 2021 Mar 26;10(2):201-204. doi: 10.1093/jpids/piaa039.
Abstract
UNLABELLED
Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB.
CLINICAL TRIALS REGISTRATION
NCT01751568.
摘要
未加标签
药物相互作用限制了同时患有人类免疫缺陷病毒 (HIV) 和结核病 (TB) 的儿童的治疗选择。我们发现，对于同时接受利福平治疗结核病的 4 周至 <2 岁的 HIV 感染儿童，每天两次给予 12 mg/kg 的雷替拉韦咀嚼片（粉碎后服用），可安全地达到药代动力学目标。
临床试验注册
NCT01751568。
相似文献
1
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.拉替拉韦含药方案在接受利福平抗结核治疗的 4 周到 2 岁人类免疫缺陷病毒感染儿童中的药代动力学和安全性。
J Pediatric Infect Dis Soc. 2021 Mar 26;10(2):201-204. doi: 10.1093/jpids/piaa039.
2
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis.拉替拉韦含药方案在感染人类免疫缺陷病毒的 2-12 岁儿童中应用的药代动力学和安全性： rifampicin 治疗结核病。
AIDS. 2019 Nov 15;33(14):2197-2203. doi: 10.1097/QAD.0000000000002369.
3
Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.标准剂量拉替拉韦或依非韦伦为基础的抗逆转录病毒治疗方案用于 HIV 和结核病合并感染患者（ANRS 12 300 Reflate TB 2）：一项开放标签、非劣效性、随机、3 期临床试验。
Lancet Infect Dis. 2021 Jun;21(6):813-822. doi: 10.1016/S1473-3099(20)30869-0. Epub 2021 Mar 2.
4
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.不同雷替格拉韦制剂在儿童 HIV-1 患者中的 240 周安全性和疗效：一项 1/2 期、开放性标签、非随机、多中心试验。
Lancet HIV. 2018 Dec;5(12):e715-e722. doi: 10.1016/S2352-3018(18)30257-1.
5
Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.拉替拉韦在利福平为基础的抗结核治疗的 HIV 感染患者中的药代动力学。
Clin Infect Dis. 2015 Oct 15;61(8):1328-35. doi: 10.1093/cid/civ477. Epub 2015 Jun 23.
6
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.拉替拉韦治疗 HIV 和结核分枝杆菌合并感染患者（ANRS 12 180 Reflate TB）：一项多中心、2 期、非对照、开放标签、随机试验。
Lancet Infect Dis. 2014 Jun;14(6):459-67. doi: 10.1016/S1473-3099(14)70711-X. Epub 2014 Apr 9.
7
Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.洛匹那韦/利托那韦加倍剂量联合利福平与洛匹那韦/利托那韦联合每日利福布丁治疗人类免疫缺陷病毒/结核分枝杆菌合并感染的安全性和药代动力学。
Clin Infect Dis. 2021 Aug 16;73(4):706-715. doi: 10.1093/cid/ciab097.
8
Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.利福平在因严重结核病住院治疗的儿童中的药代动力学，包括感染和未感染人类免疫缺陷病毒的儿童。
BMC Med. 2009 Apr 22;7:19. doi: 10.1186/1741-7015-7-19.
9
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.多拉韦林每日两次给药治疗儿童 HIV 相关结核病：在开放性标签、多中心、随机、非劣效性 ODYSSEY 试验中的药代动力学和安全性研究。
Lancet HIV. 2022 Sep;9(9):e627-e637. doi: 10.1016/S2352-3018(22)00160-6. Epub 2022 Jul 19.
引用本文的文献
1
Review on fluorinated nucleoside/non-nucleoside FDA-approved antiviral drugs.关于美国食品药品监督管理局（FDA）批准的氟化核苷/非核苷抗病毒药物的综述。
RSC Adv. 2022 Oct 31;12(48):31032-31045. doi: 10.1039/d2ra05370e. eCollection 2022 Oct 27.
2
Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.抗逆转录病毒和抗结核药物在 HIV/TB 合并感染儿童中的药代动力学：系统评价。
J Antimicrob Chemother. 2020 Dec 1;75(12):3433-3457. doi: 10.1093/jac/dkaa328.
本文引用的文献
1
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis.拉替拉韦含药方案在感染人类免疫缺陷病毒的 2-12 岁儿童中应用的药代动力学和安全性： rifampicin 治疗结核病。
AIDS. 2019 Nov 15;33(14):2197-2203. doi: 10.1097/QAD.0000000000002369.
2
Treating young children co-infected with tuberculosis and HIV.治疗同时感染结核病和艾滋病病毒的幼儿。
Lancet HIV. 2018 Dec 6. doi: 10.1016/S2352-3018(18)30326-6.
3
Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study.与不含利福平的洛匹那韦-利托那韦相比，在接受基于利福平的抗结核治疗的年轻HIV感染儿童中洛匹那韦-利托那韦超增效：一项药代动力学建模与临床研究。
Lancet HIV. 2018 Dec 6. doi: 10.1016/S2352-3018(18)30293-5.
4
Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.奈韦拉平或依非韦伦用于结核病与艾滋病病毒合并感染患者：暴露与病毒学失败的关系
J Antimicrob Chemother. 2015 Jan;70(1):225-32. doi: 10.1093/jac/dku348. Epub 2014 Sep 18.
5
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.强效药物代谢酶诱导剂利福平对拉替拉韦药代动力学的影响。
Antimicrob Agents Chemother. 2009 Jul;53(7):2852-6. doi: 10.1128/AAC.01468-08. Epub 2009 May 11.
6
Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.利福平对合并结核病的HIV感染儿童中依非韦伦药代动力学的影响。
J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):439-43. doi: 10.1097/QAI.0b013e31819c33a3.
Zotero 插件